Cargando…
Access to unlicensed medicines, who should pay when they are not provided for free?
The rising cost of clinical development, license submissions, commercial product launches, and affiliate management in all countries around the world, coupled with the ethical obligation to ensure that eligible patients have access to new treatments, has led some pharmaceutical and biopharmaceutical...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413611/ https://www.ncbi.nlm.nih.gov/pubmed/36204500 http://dx.doi.org/10.1177/23992026211040047 |